Assertio Holdings Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Assertio Holdings hat in der Vergangenheit keine Dividende gezahlt.

Wichtige Informationen

n/a

Dividendenausschüttung

n/a

Ausschüttungsquote

Durchschnittlicher Branchenertrag	2.2%
Nächster Dividendenzahlungstermin	n/a
Ex-Dividendendatum	n/a
Dividende pro Aktie	n/a
Gewinn pro Aktie	-US$3.62
Prognose der Dividendenrendite	n/a

Aktuelle Dividendenentwicklung

Keine Aktualisierungen

Recent updates

Is Assertio Holdings (NASDAQ:ASRT) Using Debt Sensibly?

Sep 25

Assertio Holdings, Inc. (NASDAQ:ASRT) Not Doing Enough For Some Investors As Its Shares Slump 30%

Aug 19

There's No Escaping Assertio Holdings, Inc.'s (NASDAQ:ASRT) Muted Revenues Despite A 36% Share Price Rise

Jul 04

Assertio Holdings, Inc. (NASDAQ:ASRT) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

May 07

Does Assertio Holdings (NASDAQ:ASRT) Have A Healthy Balance Sheet?

Apr 18

Improved Revenues Required Before Assertio Holdings, Inc. (NASDAQ:ASRT) Stock's 26% Jump Looks Justified

Mar 13

We Think Assertio Holdings (NASDAQ:ASRT) Can Stay On Top Of Its Debt

Apr 26

Is There An Opportunity With Assertio Holdings, Inc.'s (NASDAQ:ASRT) 23% Undervaluation?

Mar 02

Stabilität und Wachstum des Zahlungsverkehrs

Rufe Dividendendaten ab

Stabile Dividende: Es liegen keine ausreichenden Daten vor, um festzustellen, ob die Dividende je Aktie von ASRT in der Vergangenheit stabil war.

Wachsende Dividende: Unzureichende Daten, um festzustellen, ob die Dividendenzahlungen von ASRT gestiegen sind.

Dividendenrendite im Vergleich zum Markt

Assertio Holdings Dividendenrendite im Vergleich zum Markt

Wie sieht die Dividendenrendite von ASRT im Vergleich zum Markt aus?
Segment	Dividendenrendite
Unternehmen (ASRT)	n/a
Untere 25 % des Marktes (US)	1.4%
Markt Top 25 % (US)	4.3%
Branchendurchschnitt (Pharmaceuticals)	2.2%
Analystenprognose (ASRT) (bis zu 3 Jahre)	n/a

Bemerkenswerte Dividende: Es ist nicht möglich, die Dividendenrendite von ASRT im Vergleich zu den unteren 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Hohe Dividende: Es ist nicht möglich, die Dividendenrendite von ASRT im Vergleich zu den besten 25 % der Dividendenzahler zu bewerten, da das Unternehmen keine aktuellen Ausschüttungen gemeldet hat.

Gewinnausschüttung an die Aktionäre

Abdeckung der Erträge: Unzureichende Daten zur Berechnung der Ausschüttungsquote von ASRT, um festzustellen, ob die Dividendenzahlungen durch die Gewinne gedeckt sind.

Barausschüttung an die Aktionäre

Cashflow-Deckung: Es ist nicht möglich, die Nachhaltigkeit der Dividende zu berechnen, da ASRT keine Ausschüttungen gemeldet hat.

Assertio Holdings Dividende

Zukünftiges Wachstum Kriterienprüfungen 0/6

Wichtige Informationen

Aktuelle Dividendenentwicklung

Recent updates

Is Assertio Holdings (NASDAQ:ASRT) Using Debt Sensibly?

Assertio Holdings, Inc. (NASDAQ:ASRT) Not Doing Enough For Some Investors As Its Shares Slump 30%

Consensus EPS estimates fall by 20%

New minor risk - Profitability

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Assertio Holdings, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Buxton Helmsley Issues Letter to the Board of Directors of Assertio Holdings

There's No Escaping Assertio Holdings, Inc.'s (NASDAQ:ASRT) Muted Revenues Despite A 36% Share Price Rise

Assertio Holdings, Inc. Announces the Appointment of Brendan P. O’Grady as CEO

The Buxton Helmsley Group Sends Letter to Assertio Holdings

The Buxton Helmsley Group Sends Letter to Assertio Holdings

Assertio Holdings, Inc. Reiterates Earnings Guidance for the Year 2024

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Assertio Holdings, Inc. (NASDAQ:ASRT) Stock Catapults 29% Though Its Price And Business Still Lag The Industry

Assertio Holdings, Inc. to Report Q1, 2024 Results on May 06, 2024

Does Assertio Holdings (NASDAQ:ASRT) Have A Healthy Balance Sheet?

Assertio Holdings, Inc., Annual General Meeting, May 23, 2024

Consensus revenue estimates fall by 27%

Improved Revenues Required Before Assertio Holdings, Inc. (NASDAQ:ASRT) Stock's 26% Jump Looks Justified

Full year 2023 earnings: EPS misses analyst expectations

Assertio Holdings, Inc. Provides Earnings Guidance for the Year 2024

Assertio Holdings, Inc. to Report Q4, 2023 Results on Mar 11, 2024

New major risk - Share price stability

Assertio Holdings, Inc. Announces the Resignation of Daniel A. Peisert as Member of the Board of Directors

Bragar Eagel & Squire, P.C. Announces Class Action Lawsuit Against Assertio Holdings, Inc

Assertio Holdings, Inc. Announces Executive Changes

Assertio Holdings, Inc. Appoints Sravan Emany to Its Board of Directors

New minor risk - Market cap size

Assertio Holdings, Inc. Announces CFO Changes

New minor risk - Profitability

Consensus EPS estimates fall by 18%

Assertio Holdings, Inc. to Report Q3, 2023 Results on Nov 08, 2023

President recently sold US$479k worth of stock

President notifies of intention to sell stock

New major risk - Shareholder dilution

Independent Director notifies of intention to sell stock

New minor risk - Share price stability

Assertio Holdings, Inc. has completed a Follow-on Equity Offering in the amount of $25 million.

Consensus revenue estimates increase by 13%, EPS downgraded

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Assertio Holdings, Inc. Withdraws Earnings Guidance for the Year 2023

Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).

Assertio Holdings, Inc. Appoints Jeffrey Vacirca to Its Board of Directors

Assertio Holdings, Inc. to Report Q2, 2023 Results on Aug 03, 2023

Independent Director recently sold US$652k worth of stock

President exercised options and sold US$2.9m worth of stock

Consensus EPS estimates fall by 30%, revenue upgraded

Assertio Holdings, Inc. Raises Earnings Guidance for the Full Year of 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Independent Director notifies of intention to sell stock

Investor sentiment deteriorates as stock falls 17%

We Think Assertio Holdings (NASDAQ:ASRT) Can Stay On Top Of Its Debt

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Now 21% undervalued

Price target increased by 9.6% to US$7.88

Is There An Opportunity With Assertio Holdings, Inc.'s (NASDAQ:ASRT) 23% Undervaluation?

Investor sentiment improves as stock rises 18%

Consensus EPS estimates increase by 164%

President exercised options and sold US$257k worth of stock

Investor sentiment improves as stock rises 16%

Consensus EPS estimates increase by 11%

Investor sentiment deteriorated over the past week

Insufficient new directors

Assertio Holdings, Inc. Revises Net Product Sales Guidance for the Year 2022

Assertio Holdings, Inc. Revises Earnings Guidance for the Full Year 2022

Assertio Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Assertio Holdings Looks Good To Rebound After Recent Price Plunge

Assertio Holdings: Substantial Upside

Assertio Holdings, Inc. Raises Earnings Guidance for the Year 2022

Assertio Therapeutics Q2 2022 Earnings Preview

Assertio Holdings, Inc. to Report Q2, 2022 Results on Aug 08, 2022

Assertio Holdings: Management Still Swimming Against The Tide

Assertio's Phenomenal Turnaround

Assertio Holdings, Inc. Re-Affirms Sales Guidance for the Full Year of 2022

Levi & Korsinsky, LLP Announces Propose Settlement Against Assertio Therapeutics, Inc. Securities Litigation